Praxis Precision Medicines Inc (PRAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
Praxis Precision Medicines Inc (PRAX) Earnings: Report Dates and Results
Praxis Precision Medicines (PRAX) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Praxis Precision Medicines reported EPS of -$3.23, above the -$3.68 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRAX has an expected report date of Feb 17, 2027.
PRAX Earnings Call
The latest PRAX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 25 quarters below that had an estimate, PRAX beat 11 and missed 14. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 135.14% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$3.23 | -$3.68 | -$5.60 - -$2.74 | +12.23% | Beat | N/A | 19 | 0 up, 0 down | Nov 9, 2026 | N/A |
| Jun 30, 2026 | -$2.87 | -$3.60 | -$5.33 - -$3.04 | +20.28% | Beat | N/A | 16 | N/A | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$3.20 | -$3.68 | -$5.23 - -$2.98 | +13.04% | Beat | N/A | 12 | 1 up, 4 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$3.50 | -$3.13 | -$4.16 - -$2.17 | -11.82% | Miss | N/A | 14 | 1 up, 1 down | Feb 19, 2026 | N/A |
| Sep 30, 2025 | -$3.36 | -$3.45 | -$4.06 - -$3.10 | +2.61% | Beat | N/A | 12 | 0 up, 1 down | Nov 5, 2025 | N/A |
| Jun 30, 2025 | -$3.31 | -$3.36 | -$3.96 - -$2.93 | +1.49% | Beat | N/A | 10 | 0 up, 1 down | Aug 4, 2025 | N/A |
| Mar 31, 2025 | -$3.29 | -$3.21 | -$3.69 - -$2.77 | -2.49% | Miss | N/A | 9 | 1 up, 6 down | May 2, 2025 | N/A |
| Dec 31, 2024 | -$2.94 | -$2.82 | -$3.23 - -$2.41 | -4.29% | Miss | N/A | 9 | 0 up, 2 down | Feb 28, 2025 | $7.46M |
| Sep 30, 2024 | -$2.75 | -$1.95 | -$2.23 - -$1.74 | -41.03% | Miss | N/A | 10 | 0 up, 0 down | Nov 6, 2024 | $302000 |
| Jun 30, 2024 | -$1.74 | -$2.32 | -$3.24 - -$1.72 | +25.00% | Beat | N/A | 10 | 0 up, 0 down | Aug 13, 2024 | $357000 |
| Mar 31, 2024 | -$2.84 | -$2.16 | -$2.24 - -$1.72 | -31.48% | Miss | N/A | 7 | 0 up, 0 down | May 13, 2024 | $431000 |
| Dec 31, 2023 | -$2.97 | -$3.18 | -$3.59 - -$2.99 | +6.60% | Beat | N/A | 6 | 1 up, 0 down | Mar 5, 2024 | $515000 |
| Sep 30, 2023 | -$2.70 | -$4.89 | -$7.80 - -$4.05 | +44.79% | Beat | N/A | 6 | 1 up, 0 down | Nov 7, 2023 | $468000 |
| Jun 30, 2023 | -$7.35 | -$10.60 | -$11.09 - -$7.65 | +30.66% | Beat | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | $781000 |
| Mar 31, 2023 | -$10.65 | -$12.80 | -$13.64 - -$8.70 | +16.80% | Beat | N/A | 4 | 0 up, 0 down | May 11, 2023 | $683000 |
| Dec 31, 2022 | -$13.05 | -$12.03 | -$16.04 - -$9.60 | -8.48% | Miss | N/A | 6 | 0 up, 0 down | Feb 7, 2023 | N/A |
| Sep 30, 2022 | -$14.40 | -$14.01 | -$17.39 - -$10.34 | -2.78% | Miss | N/A | 5 | 0 up, 0 down | Nov 9, 2022 | N/A |
| Jun 30, 2022 | -$19.80 | -$19.27 | N/A | -2.75% | Miss | N/A | N/A | 1 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$1.51 | -$1.30 | -$1.41 - -$1.18 | -16.15% | Miss | N/A | 6 | 1 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | -$19.50 | -$16.05 | -$17.84 - -$13.94 | -21.50% | Miss | N/A | 6 | N/A | Feb 28, 2022 | N/A |
| Sep 30, 2021 | -$15.00 | -$13.95 | -$15.59 - -$12.14 | -7.53% | Miss | N/A | 5 | N/A | Nov 3, 2021 | N/A |
| Jun 30, 2021 | -$13.20 | -$10.12 | -$11.84 - -$9.45 | -30.43% | Miss | N/A | 4 | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | -$10.65 | -$11.14 | -$13.64 - -$8.70 | +4.40% | Beat | N/A | 4 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$0.87 | -$0.37 | -$0.46 - -$0.29 | -135.14% | Miss | N/A | 2 | N/A | Mar 17, 2021 | N/A |
| Sep 30, 2020 | -$7.90 | -$4.42 | -$23.99 - -$4.05 | -78.73% | Miss | N/A | 3 | N/A | Oct 16, 2020 | N/A |
| Jun 30, 2020 | -$3.90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 2, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$13.46, after -$10.27 the year before. It was -$12.67 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$13.46 | N/A |
| Dec 31, 2024 | -$10.27 | N/A |
| Dec 31, 2023 | -$23.67 | N/A |
| Dec 31, 2022 | -$48.76 | N/A |
| Dec 31, 2021 | -$58.35 | N/A |
| Dec 31, 2020 | -$12.67 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,874 | 23 | |
| 2026Q1 | Mar 31, 2026 | 6,670 | 17 | |
| 2025Q4 | Dec 31, 2025 | 7,699 | 18 | |
| 2025Q2 | Jun 30, 2025 | 6,660 | 14 | |
| 2024Q3 | Sep 30, 2024 | 5,802 | 12 |
2026Q2 Earnings Call
Opening remarks
Daniel Ferry Managing Director, LifeSci Advisors Good morning, and welcome to the Praxis Precision Medicines Second Quarter 2026 Financial Results and Business Update Conference Call. This call is being webcast live and can be accessed on the Investors section of Praxis' website at www.praxismedicines.com. Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines and financial projections. While these forward-looking statements represent Praxis' views as of today, they should not be relied upon as representing the company's views in the future. Praxis may update these statements in the future, but is not taking on an obligation to do so. Please refer to Praxis' most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business. Joining us on today's call are Marcio DeSouza, President and Chief Executive Officer of Praxis; and Tim Kelly, our Chief Financial Officer. After providing updates on our key programs, we'll move to a brief Q&A session where Marcio and Tim will be joined by Steve Petrou, President of Research and Development; and Megan Sniecinski, Chief Operating Officer. With that, it's my pleasure to turn the call over to Marcio. Marcio?
Marcio DeSouza President and Chief Executive Officer Thank you, Dan. Good morning, everyone. Thank you for joining Praxis Second Quarter 2026 Conference Call. Three months ago, I told you this would be the year Praxis becomes a commercial company. This quarter is the one where that stopped being a plan and started materializing into the organization. We have two NDAs in late-stage review with the FDA with both approvals expected in about six months. It's extremely exciting to bring both ulixacaltamide to ET patients and relutrigine to SCN2A and SCN8A patients. We have commercial leadership in place, a field force for the first launch hires and training and a distribution network established and inventory being built. I want to spend most of my time today on some key regulatory developments and what we have been building. Let me start with ulixacaltamide. Essential tremor affects over 7 million Americans, and there is still no FDA-approved therapy developed specifically to treat the condition. With the potential approval coming up by January next year, ulixacaltamide is poised to change that. Speaking about the NDA review, the FDA completed its mid-cycle communications with us and we are very pleased with the progress and discussions with the agency. In that meeting, the agency identified no efficacy-related significant issues and stated that it does not plan to request an advisory committee meeting. I would characterize the discussion as expected and very forward-looking.
Frequently Asked Questions About PRAX
When is Praxis Precision Medicines's next earnings date?
Praxis Precision Medicines's next earnings report is expected for Feb 17, 2027.
Did PRAX beat earnings estimates last quarter?
Yes. Praxis Precision Medicines reported EPS of -$3.23 for the quarter ended Sep 30, 2026, above the -$3.68 estimate, a 12.23% surprise.
What EPS do analysts expect from PRAX next quarter?
The consensus EPS estimate for Praxis Precision Medicines for the quarter ending Dec 31, 2026 is -$4.00 from 23 analysts, with estimates from -$5.04 to -$1.05.
How often does PRAX beat earnings estimates?
Praxis Precision Medicines beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.88%.
PRAX pages: Overview, Earnings, Forecast, Financials, Competitors